A 2025 study of 438 postmenopausal women found those taking diabetes drug metformin had a 30 percent lower risk of dying before age 90 compared to those taking sulfonylurea, adding to evidence that metformin may slow aging through its effects on DNA damage, gene activity, and multiple biological pathways.
A 2025 study published in the Journal of Gerontology: Medical Sciences suggests that metformin, a widely used type 2 diabetes medication, may significantly increase the chances of “exceptional longevity” in postmenopausal women. Researchers from the U.S. and Germany analyzed data from the long-term Women’s Health Initiative, finding that women who initiated metformin treatment had a 30 percent lower risk of dying before age 90 compared to those taking sulfonylureas.
Known as a “gerotherapeutic,” metformin is believed to slow aging by limiting DNA damage and promoting gene activity associated with resilience. While the study—a “target trial emulation”—cannot prove direct cause and effect due to its observational nature, it offers a rare panoramic view of health outcomes over 15 years, reinforcing the hypothesis that biological aging is malleable and potentially treatable.
NEWS NOW:
- Nicki Minaj responds to Newsom’s ‘I’m a 960 SAT guy. I can’t read’
- WATCH: Fareed Zakaria’s take on blue cities
- Kash Patel responds following backlash for celebrating with US hockey team while on work trip
- Cartels attack civilian targets across Mexico after U.S.-Mexico mission kills drug leader ‘El Mencho’